De Novo Biosynthesis of Antidepressant Psilocybin in Escherichia coli
Microbial Biotechnology · 2025-04 · 18 (4)
DOI: 10.1111/1751-7915.70135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, online erschienen am 03.04.2025. Verfasst von Zhangrao Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Escherichia coli, Psilocybin, Antidepressive Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Psilocybin, a tryptamine‐derived alkaloid, has been granted Breakthrough Therapy designation by the U.S. FDA for treatment‐resistant depression, underscoring its clinical importance. Therefore, sustainable and economic production is urgently needed. Manufacturing of psilocybin in Escherichia coli has drawn great attention. However, due to the low expression and activity of the eukaryotic cytochrome P450 enzyme PsiH in the psilocybin biosynthetic pathway, de novo synthesis of psilocybin in prokaryotic cells has been hampered. To overcome this dilemma, we herein demonstrated de novo synthesis of psilocybin in E. coli by constructing PsiH variants with N‐terminal domain modifications and expressing the entire biosynthetic pathway at a concordantly low temperature. Improving the supply of precursor and engineering the P450 electron transfer chain resulted in a 33‐fold increase in the titre of norbaeocystin (105.3 mg/L), a key intermediate of psilocybin biosynthesis, and a 17‐fold increase in the titre of psilocybin (14 mg/L). Further enhancement of psilocybin production was achieved by converting norbaeocystin to psilocybin by overexpressing an extra copy of the methyltransferase gene psiM . Finally, 79.4 mg/L of psilocybin was produced by optimising flask fermentation conditions, a 100‐fold improvement over the starting strain. Our work demonstrates the successful fungal P450 engineering to improve the catalytic activity in E. coli and will advance the sustainable production of the important antidepressant psilocybin in prokaryotic microbial cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People's Republic of China.
- University of Chinese Academy of Sciences, Beijing, People's Republic of China.
ORCID-Profile: Yongpeng Yao, Gang Liu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Huang, Z., Yao, Y., Di, R., Zhang, J., Pan, Y., & Liu, G. (2025). De Novo Biosynthesis of Antidepressant Psilocybin in Escherichia coli. Microbial Biotechnology, 18(4). https://doi.org/10.1111/1751-7915.70135
Vancouver
Huang Z, Yao Y, Di R, Zhang J, Pan Y, Liu G. De Novo Biosynthesis of Antidepressant Psilocybin in Escherichia coli. Microbial Biotechnology. 2025;18(4). doi:10.1111/1751-7915.70135
BibTeX
@article{Huang2025,
author = {Huang, Zhangrao and Yao, Yongpeng and Di, Rouyu and Zhang, JianChao and Pan, Yuanyuan and Liu, Gang},
title = {De Novo Biosynthesis of Antidepressant Psilocybin in Escherichia coli},
journal = {Microbial Biotechnology},
year = {2025},
volume = {18},
number = {4},
doi = {10.1111/1751-7915.70135}
}
EUVIMED